• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Expanding access to sickle cell gene therapies for patients with Medicaid

August 6, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
Sickle cell disease
4
SHARES
8
VIEWS
Share on FacebookShare on Twitter


Sickle cell disease
Credit: National Institutes of Health

Connecticut is now participating in a new federal program aimed at expanding treatment access for patients with sickle cell disease who are insured through Medicaid.

Through the Cell and Gene Therapy Access Model established by the Centers for Medicare and Medicaid Services (CMS), costs of cell and gene therapies for sickle cell disease will be tied to how well the drugs work in patients. If the treatments don’t work to their full potential, states participating in the program will receive discounts and rebates from the drug manufacturers.

The U.S. Food and Drug Administration approved two gene therapies for sickle cell disease—exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia)—that, while potentially curative, are costly, priced at $2.2 million and $3.1 million per patient, respectively. The model is intended to make it easier for participating states to pay for these gene therapies.

Lakshmanan Krishnamurti, MD, professor of pediatrics (hematology/oncology) at Yale School of Medicine and chief of pediatric hematology, oncology, and bone marrow transplant at Yale New Haven Children’s Hospital, worked with Yale Cancer Center, Yale New Haven Hospital (YNHH), and the state of Connecticut to bring this program to the state. Both gene therapies are offered at YNHH.

“This important program will enable patients to have access to this life-changing new therapy for sickle cell disease,” says Clifford Bogue, MD, Waldemar Von Zedtwitz Professor of Pediatrics, chair of the Department of Pediatrics at Yale School of Medicine, and chief of pediatrics at Yale New Haven Health. “We are excited that Connecticut is one of the participating states.”

The Cell and Gene Therapy Access Model is the first of its kind in the United States. Connecticut is among 33 states currently participating, along with Washington, D.C. and Puerto Rico, which together represent 84% of Medicaid beneficiaries with sickle cell disease. CMS says other conditions may be added to the model in the future.

New treatments for sickle cell disease

In people with sickle cell disease, red blood cells that are typically smooth, round, and flexible are instead hard, crescent-shaped, and brittle. These malformed cells break down faster and can scratch and block blood vessels, leading to severe pain, inflammation, organ damage, infection, and even stroke. Sickle cell disease affects an estimated 100,000 Americans.

Prior to gene therapy, the only potential cure for patients was a bone marrow transplant, an option available to only around 25% of patients. For the other 75%, lifelong management includes medications to reduce blood cell sickling, pain treatment, and blood transfusions.

Both approved gene therapies for sickle cell disease are intended to be one-time treatments. Each takes a different approach, but both ultimately reprogram the body’s blood stem cells, leading them to produce healthy red blood cells in amounts that dilute the sickle cells.

In clinical trials, 93.5% of patients receiving Casgevy and 88% of those receiving Lyfgenia experienced no vaso-occlusion events—in which sickle cells block blood vessels, causing severe pain and, over time, organ damage—in the months following treatment.

“Gene therapies have the potential to be transformative for patients with sickle cell disease,” says Krishnamurti. “Freed from disabling pain, patients have the possibility of normalcy for the first time in their lives.

“CMS has taken a major step forward to make these treatments available at a reasonable cost and to implement these programs in a way that improves access to these complex treatments. The Cell and Gene Therapy Access Model for sickle cell is likely to be a forerunner for similar treatments for many diseases in the future.”

Provided by
Yale University


Citation:
Expanding access to sickle cell gene therapies for patients with Medicaid (2025, August 6)
retrieved 6 August 2025
from https://medicalxpress.com/news/2025-08-access-sickle-cell-gene-therapies.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Sickle cell disease
Credit: National Institutes of Health

Connecticut is now participating in a new federal program aimed at expanding treatment access for patients with sickle cell disease who are insured through Medicaid.

Through the Cell and Gene Therapy Access Model established by the Centers for Medicare and Medicaid Services (CMS), costs of cell and gene therapies for sickle cell disease will be tied to how well the drugs work in patients. If the treatments don’t work to their full potential, states participating in the program will receive discounts and rebates from the drug manufacturers.

The U.S. Food and Drug Administration approved two gene therapies for sickle cell disease—exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia)—that, while potentially curative, are costly, priced at $2.2 million and $3.1 million per patient, respectively. The model is intended to make it easier for participating states to pay for these gene therapies.

Lakshmanan Krishnamurti, MD, professor of pediatrics (hematology/oncology) at Yale School of Medicine and chief of pediatric hematology, oncology, and bone marrow transplant at Yale New Haven Children’s Hospital, worked with Yale Cancer Center, Yale New Haven Hospital (YNHH), and the state of Connecticut to bring this program to the state. Both gene therapies are offered at YNHH.

“This important program will enable patients to have access to this life-changing new therapy for sickle cell disease,” says Clifford Bogue, MD, Waldemar Von Zedtwitz Professor of Pediatrics, chair of the Department of Pediatrics at Yale School of Medicine, and chief of pediatrics at Yale New Haven Health. “We are excited that Connecticut is one of the participating states.”

The Cell and Gene Therapy Access Model is the first of its kind in the United States. Connecticut is among 33 states currently participating, along with Washington, D.C. and Puerto Rico, which together represent 84% of Medicaid beneficiaries with sickle cell disease. CMS says other conditions may be added to the model in the future.

New treatments for sickle cell disease

In people with sickle cell disease, red blood cells that are typically smooth, round, and flexible are instead hard, crescent-shaped, and brittle. These malformed cells break down faster and can scratch and block blood vessels, leading to severe pain, inflammation, organ damage, infection, and even stroke. Sickle cell disease affects an estimated 100,000 Americans.

Prior to gene therapy, the only potential cure for patients was a bone marrow transplant, an option available to only around 25% of patients. For the other 75%, lifelong management includes medications to reduce blood cell sickling, pain treatment, and blood transfusions.

Both approved gene therapies for sickle cell disease are intended to be one-time treatments. Each takes a different approach, but both ultimately reprogram the body’s blood stem cells, leading them to produce healthy red blood cells in amounts that dilute the sickle cells.

In clinical trials, 93.5% of patients receiving Casgevy and 88% of those receiving Lyfgenia experienced no vaso-occlusion events—in which sickle cells block blood vessels, causing severe pain and, over time, organ damage—in the months following treatment.

“Gene therapies have the potential to be transformative for patients with sickle cell disease,” says Krishnamurti. “Freed from disabling pain, patients have the possibility of normalcy for the first time in their lives.

“CMS has taken a major step forward to make these treatments available at a reasonable cost and to implement these programs in a way that improves access to these complex treatments. The Cell and Gene Therapy Access Model for sickle cell is likely to be a forerunner for similar treatments for many diseases in the future.”

Provided by
Yale University


Citation:
Expanding access to sickle cell gene therapies for patients with Medicaid (2025, August 6)
retrieved 6 August 2025
from https://medicalxpress.com/news/2025-08-access-sickle-cell-gene-therapies.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

4 people die in crash of medical transport plane on Navajo Nation in northern Arizona

Next Post

Award recognizes leadership in sustainable water management

Related Posts

cancer patient

Computational tool ranks compounds to improve cancer immunotherapy effectiveness

August 6, 2025
5
prison

New European toolkit launched to help eliminate hepatitis in prisons

August 6, 2025
4
Next Post
Four people in evening dress, one of them holding an award, look towards the camera

Award recognizes leadership in sustainable water management

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Super Micro Computer stock falls as much as 16% after quarterly results, profit forecast miss estimates

August 6, 2025
‘Political circus’: Halifax council reverses bike lane decision after premier warning - Halifax

‘Political circus’: Halifax council reverses bike lane decision after premier warning – Halifax

August 6, 2025
Dubai Insurance, Aster DM unveil new insurance plan

Sukoon Insurance affirms strong market position following S&P Global Ratings bulletin

August 6, 2025
Copy Link

LaLiga’s top 2025-26 kits: Barcelona, Real Madrid, Atlético, more

August 6, 2025

Recent News

Super Micro Computer stock falls as much as 16% after quarterly results, profit forecast miss estimates

August 6, 2025
1
‘Political circus’: Halifax council reverses bike lane decision after premier warning - Halifax

‘Political circus’: Halifax council reverses bike lane decision after premier warning – Halifax

August 6, 2025
7
Dubai Insurance, Aster DM unveil new insurance plan

Sukoon Insurance affirms strong market position following S&P Global Ratings bulletin

August 6, 2025
3
Copy Link

LaLiga’s top 2025-26 kits: Barcelona, Real Madrid, Atlético, more

August 6, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Super Micro Computer stock falls as much as 16% after quarterly results, profit forecast miss estimates

August 6, 2025
‘Political circus’: Halifax council reverses bike lane decision after premier warning - Halifax

‘Political circus’: Halifax council reverses bike lane decision after premier warning – Halifax

August 6, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co